U.S. markets open in 7 hours 31 minutes
  • S&P Futures

    3,859.25
    +11.00 (+0.29%)
     
  • Dow Futures

    31,095.00
    +82.00 (+0.26%)
     
  • Nasdaq Futures

    11,928.50
    +48.25 (+0.41%)
     
  • Russell 2000 Futures

    1,734.70
    +6.10 (+0.35%)
     
  • Crude Oil

    98.73
    +0.20 (+0.20%)
     
  • Gold

    1,745.30
    +8.80 (+0.51%)
     
  • Silver

    19.29
    +0.13 (+0.68%)
     
  • EUR/USD

    1.0222
    +0.0037 (+0.37%)
     
  • 10-Yr Bond

    2.9130
    0.0000 (0.00%)
     
  • Vix

    26.73
    -0.81 (-2.94%)
     
  • GBP/USD

    1.1950
    +0.0028 (+0.24%)
     
  • USD/JPY

    135.9170
    +0.0020 (+0.00%)
     
  • BTC-USD

    20,306.15
    +254.01 (+1.27%)
     
  • CMC Crypto 200

    441.65
    +6.12 (+1.41%)
     
  • FTSE 100

    7,107.77
    +82.30 (+1.17%)
     
  • Nikkei 225

    26,439.77
    +332.12 (+1.27%)
     

Celldex to Host Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Conference Call

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc.

HAMPTON, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced it will host a conference call and webcast on Monday, February 28, 2022 at 4:30 p.m. ET to discuss its fourth quarter and full year 2021 financial results and corporate highlights.

To access a live or recorded webcast of the call, please visit the "Events & Presentations" page under the "Investors & Media" section of the Celldex Therapeutics website at www.celldex.com. The call can also be accessed by dialing (866) 743-9666 (United States) or (760) 298-5103 (international). The conference call passcode is 2177774.

About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.

Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com

Patrick Till
Senior Director, Investor Relations & Corporate Communications
(484) 788-8560
ptill@celldex.com